Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on May 11, 2022 10:20am
101 Views
Post# 34673769

RE:RE:RE:Nice buy-backs !!!!

RE:RE:RE:Nice buy-backs !!!!
gudisgood wrote:

We're steady approaching 115 million outstanding shares. If the shares are undervalued -- which I certainly believe them to be, and Goodman/Samira seem to agree -- they keep adding value to shareholders (potentially significant value!) with this extremely simple action.

At the same time, I do hope they find other productive uses for the money soon. Whenever they spend on money share buybacks, it means that's the best use of money they can think of. It's great to take an advantage of the share price... but it would be even nicer if they had better opportunities. :)




I agree. Although these purchases can be mostly funded through cash from ops or divesting from some loans or funds. If they believe the stock will be $7-8 in a year than hard to beat that easy 40% 12 month return. Especially when they can manage both. 

<< Previous
Bullboard Posts
Next >>